![]() ![]() Pathologic staging was based on the 7th American Joint Committee on Cancer criteria. Systemic adjuvant chemotherapy, endocrine treatment, and radiotherapy were performed in accordance with clinical guidelines. All pathologic records included primary tumor characteristics, such as tumor size, stage, tumor grade, ER, PR, and HER2 status, and Ki67 labeling index. Finally, 505 patients were included ( Fig. Of these patients, we excluded those with bilateral breast cancer, neoadjuvant chemotherapy, in situ carcinoma, tumor size less than 0.5 cm, stage III or IV breast cancer, metastatic carcinoma from other origin, and tumors of nonepithelial origin. We retrospectively reviewed the medical records of 945 breast cancer patients who had curative surgery at our institution between 20. In this study, we compared the recurrence rates in early breast cancer patients from two groups of patients with extremely different subtypes and nodal status, luminal A-node positive (pN1) type and triple negative breast cancer (TNBC)-node negative (pN0) type, which are usually treated with chemotherapy and/or endocrine treatment. In these cases, it is not clear which patients will benefit more from chemotherapy: node-positive early breast cancer or node-negative patients with a poor prognostic subtype. However, cytotoxic chemotherapy remains the mainstay of treatment for many early breast cancer patients, especially node-positive or ER and HER2-negative patients. Tamoxifen and trastuzumab have contributed to decreased recurrence and mortality in hormone receptor-positive and HER2-positive breast cancer patients. Nonetheless, axillary lymph node metastasis remains a powerful prognostic factor that affects decision-making regarding the use of adjuvant chemotherapy in early breast cancer. Guidelines recommend treatment of breast cancer patients according to intrinsic subtype, as diagnosed by IHC staining of these surrogate markers. Each subtype has been revealed to have characteristic immunohistochemical (IHC) profiles according to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 expression status. However, gene expression profiling to identify breast cancer subtypes is not routinely used in the clinical setting due to its high cost. Many studies have shown that each subtype has different histopathological presentations and prognostic outcomes. Intrinsic subtypes of breast cancer, according to gene expression profiling, were first recognized by Perou et al. Breast cancer has been shown to be a heterogeneous group of diseases at the molecular, pathological, and clinical level.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |